Efficacy News and Research

RSS

Textiles with permanent antibacterial properties

Antimicrobial agents are not new to the marketplace. Our stores are filled with antibacterial soaps and gels, and in a post-9/11 world, wearable protection from biological agents is in increasing demand. So far, antimicrobial textile production has used coatings that can wash away over time, reducing the useful life of protective clothing.

21 Jun 2005

Safety warning on Internet drugs

Thousands of men in the UK buy “lifestyle drugs” such as erectile dysfunction medication, weight and hair loss products from websites and are oblivious to the fact that some (not all) of the websites belong to unscrupulous vendors.

21 Jun 2005

New cardiovascular drug derived from Dan Shen (Saliva miltiorrhiza)

Through a large number of clinical trials over the past 3 years, researchers from the CAS Shanghai Institute of Materia Medica (SIMM) have developed a new cardiovascular drug with a definite effective component extracted from Dan Shen (Saliva miltiorrhiza), a medicinal herb widely used in China.

21 Jun 2005

New discoveries in treatment for patients with non-Hodgkin's lymphoma

Three scientific studies - each highlighting new discoveries in treatment for patients with non-Hodgkin's lymphoma - were announced at the Society of Nuclear Medicine's 52nd Annual Meeting June 18–22 in Toronto.

20 Jun 2005

Seroquel (quetiapine), may be an effective treatment option for patients with schizophrenia

A new study, published in the journal Human Psychopharmacology: Clinical and Experimental, shows that the atypical antipsychotic Seroquel (quetiapine), may be an effective treatment option for patients with schizophrenia who exhibit aggressive behaviour during psychotic episodes.

19 Jun 2005

Chronic insomnia medicines have not yet been rigorously evaluated for long-term use

Many of the medications widely used to manage chronic insomnia have not yet been rigorously evaluated for long-term use, according to an independent scientific panel convened this week by the National Institutes of Health.

16 Jun 2005

Tentative approval for Lamivudine tablets

The U.S. Food and Drug Administration (FDA) has announced the tentative approval of Lamivudine Tablets manufactured by Aurobindo Pharma LTD. Hyderabad, India.

16 Jun 2005

Immunomedics awarded U.S. and Australian patents

Immunomedics announced that it has received notices that the U.S. and Australian patent offices have allowed claims in respective patent applications covering methods for treating a wide range of autoimmune diseases using monoclonal antibodies that bind to the CD22 antigen present on B-lymphocytes.

16 Jun 2005

Promising new tuberculosis drug enters clinical trial

A promising new drug candidate that may be effective against both actively dividing and slow-growing Mycobacterium tuberculosis (M. tb) has begun testing in humans, the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, announced this week.

15 Jun 2005

Study examines biomarkers for response to erlotinib in glioma

Researchers have found two biomarkers that, in patients with a malignant type of brain tumor called glioblastoma multiforme, were associated with response to the cancer drug erlotinib (Tarceva).

14 Jun 2005

The most frequently used drugs for treating chronic insomnia have never been approved for that purpose

Vaughn McCall, M.D., M.S., professor and chairman of the Department of Psychiatry and Behavioral Medicine, told a special consensus panel at the National Institutes of Health (NIH) that he could find no evidence that randomized controlled clinical trials had ever been conducted for five of the 10 pharmaceuticals prescribed most often for chronic insomnia.

14 Jun 2005

Invasive treatment including stenting may be more effective for heart attack patients who arrive late at hospital

Invasive treatment including stenting may have better outcomes than conventional treatments for heart attack patients who arrive at the hospital more than 12 hours after symptoms began, according to a study in the June 15 issue of JAMA.

14 Jun 2005

Rimonabant study shows significant improvements in HbA1c and cardiometabolic risk factors in people with type 2 diabetes

The reported results of a one-year phase III study in 1045 people with type 2 diabetes treated with rimonabant, the first in a new class of therapeutic agents called selective CB1 Blockers, were that rimonabant 20 mg significantly improved HbA1c (a measure of blood sugar control), dyslipidemia (abnormal levels of fat in the blood), and systolic blood pressure with a concomitant substantial reduction in abdominal obesity in people with type 2 diabetes treated with oral anti-diabetic medications and requiring further control.

12 Jun 2005

European approval of Temodal (temozolomide) capsules for treatment of glioblastoma multiforme

Schering-Plough announced today that the European Commission has granted approval of Temodal (temozolomide) Capsules for first-line use for the treatment of patients with newly diagnosed glioblastoma multiforme (GBM), the most common and aggressive form of primary brain cancer.

10 Jun 2005

Digital mammography no better than traditional film X-rays in the ability to detect cases of breast cancer

Digital mammography provides no clear-cut improvements over traditional film X-rays in the ability to detect cases of breast cancer, says a new technology assessment report. The technology does, however, offer other benefits, including slightly lower radiation doses for patients, that may prompt its increasing use despite its much higher costs.

10 Jun 2005

Similarities in antiretroviral therapy efficacy in poorer countries to that in industrial nations

Antiretroviral therapy (ART) programs for treating HIV in developing countries are about as effective as ART programs in developed countries, according to an article in the July 15 issue of Clinical Infectious Diseases, now available online.

9 Jun 2005

Lorus Therapeutics receives patent allowance to protect novel anticancer drug

Lorus Therapeutics today announced that its wholly owned subsidiary, GeneSense Technologies Inc. (GeneSense), has received notice from the European Patent Office of its intention to grant GeneSense's application for a patent of its novel antisense drug, GTI-2501.

9 Jun 2005

MabThera highly effective in treating rheumatoid arthritis

Results from the DANCER study presented today revealed that MabThera significantly improves symptoms in heavily treated patients who are affected by moderate-to-severe rheumatoid arthritis (RA), a painful and debilitating disease of the joints.

9 Jun 2005

Rituximab, used to treat rheumatoid arthritis (RA) is safe and effective

Professor Paul Emery from the University of Leeds in the UK led the DANCER study (Double blind placebo controlled dose ranging study), designed to confirm the efficacy of rituximab for the treatment of patients with active RA who have failed to improve on one or more disease modifying anti-rheumatic drugs (DMARDs).

9 Jun 2005

Virulizin granted orphan drug status in Europe

Lorus Therapeutics has announced that the EMEA (European Medicines Agency) has given a positive opinion on Lorus' application for orphan drug status to Virulizin, the company's lead anticancer drug for the treatment of pancreatic cancer.

8 Jun 2005

Efficacy News and Research

Textiles with permanent antibacterial properties

Safety warning on Internet drugs

New cardiovascular drug derived from Dan Shen (Saliva miltiorrhiza)

New discoveries in treatment for patients with non-Hodgkin's lymphoma

Seroquel (quetiapine), may be an effective treatment option for patients with schizophrenia

Chronic insomnia medicines have not yet been rigorously evaluated for long-term use

Tentative approval for Lamivudine tablets

Immunomedics awarded U.S. and Australian patents

Promising new tuberculosis drug enters clinical trial

Study examines biomarkers for response to erlotinib in glioma

The most frequently used drugs for treating chronic insomnia have never been approved for that purpose

Invasive treatment including stenting may be more effective for heart attack patients who arrive late at hospital

Rimonabant study shows significant improvements in HbA1c and cardiometabolic risk factors in people with type 2 diabetes

European approval of Temodal (temozolomide) capsules for treatment of glioblastoma multiforme

Digital mammography no better than traditional film X-rays in the ability to detect cases of breast cancer

Similarities in antiretroviral therapy efficacy in poorer countries to that in industrial nations

Lorus Therapeutics receives patent allowance to protect novel anticancer drug

MabThera highly effective in treating rheumatoid arthritis

Rituximab, used to treat rheumatoid arthritis (RA) is safe and effective

Virulizin granted orphan drug status in Europe

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News